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AbstrAct:
The vertebrate genome contains large spans of non-coding RNA, which for the most 
part were considered of little functional value to the organism. Recent studies have 
indicated that vertebrate genomes may have stored hidden secrets in this large span 
of non-coding RNA, which we refer to here as “Natural Antisense Transcripts (NATs).” 
NATs can be found in introns, exons, promoters, enhancers, intergenic sequences, 
and untranslated regions of the genome. They can be located in either the plus or 
minus DNA strand. NATs utilize several mechanisms that include DNA replication 
interference, chromatin remodeling, transcriptional interference, RNA masking, 
double-stranded RNA (dsRNA)-dependent mechanisms and translation interference 
to mechanistically regulate gene expression. Recently, NAT levels have been identified 
as dysregulated in various disease states. This review presents an overview of the 
current state of NAT biology and highlights the main points with specific examples. 
the PrevAlence of nAturAl 
Antisense trAnscriPt (nAt) in 
vertebrAtes
Natural antisense transcript (NAT) is defined as any 
RNA transcript that is complementary to an endogenous 
RNA  transcript  [1].  Our  knowledge  about  NAT  began 
from viral transcripts. In 1969, Bovre K et al found the 
central b2 region in the coliphage λ genome could produce 
two opposite oriented mRNA, one originating on the plus 
strand and the other on the minus strand, which partially 
overlap with each other [2]. Later, similar transcriptional 
events were identified in prokaryotes [3] and eukaryotes 
[4]. Systematic identification of NATs in mammalian cells 
began in 2002 utilizing a microbead capture double strand 
cDNA  strategy  [5].  Genome-wide  analyses  show  that 
more than 63% of transcripts have antisense (AS) partners, 
most  of  which  represent  non-protein-coding  RNAs 
[6]. In human genome, 22% of the human transcription 
clusters form sense (S)/antisense (AS) pairs. Through in-
depth analysis of the functional elements in the human 
genome (1% coverage), the Encyclopedia of the DNA 
element (ENCODE) pilot project discovered that almost 
all  DNA  is  transcribed  into  RNA,  producing  a  large 
number of overlapping transcripts [7]. Several methods 
are utilized to identify NATs and are reviewed elsewhere 
[8]. Because NATs are found in low abundance, they are 
often lost in transcriptome analysis. Analysis of 29 human 
LongSAGE libraries demonstrated that antisense tag only 
contributes  8%  of  the  total  transcript  copies  [9].  The 
percentage of NATs is 2.8% in worm, 11% in yeast and 
12% in malaria [10-12]. With the completed sequencing 
of  the  human  genome,  the  gene  numbers  has  been 
revised to 25,000 [13] because more transcripts continue 
to be discovered, many of which do not correspond to 
annotated genes, but to intergenic and intronic regions. 
Most AS transcripts do not have protein-coding capacity 
[14]. At present, the Unigene database of the National 
Center for Biotechnology Information indicates 123,200 
entries for human and 79,222 for mouse. To date, protein-
coding transcripts just account for ~1.5% genome, and the 
remainder transcribe into a large amount of non-coding 
RNAs, of which NATs are dominant [13].Oncotarget 2010; 1:  447 - 452 448 www.impactjournals.com/oncotarget
underlying MechAnisMs of nAt 
function
Most S/AS transcript pairs are conserved in evolution 
and  are  concurrently  or  inversely  expressed  in  a  cell 
suggesting a correlative functional role. Six mechanisms 
widely dictate how NAT’s function: (a) DNA replication 
interference, (b) chromatin remodeling, (c) transcriptional 
interference, (d) RNA masking, (e) double-stranded RNA 
(dsRNA)-dependent  mechanisms  and  (f)  translation 
interference [15]4. We will discuss the general principles 
of each NAT mechanism followed by a specific example. 
(a) dnA replication interference
DNA  replication  can  be  interfered  and  thereby 
inhibited by NATs. This was demonstrated elegantly in the 
E. coli plasmid ColE1. The ColE1 primer transcript (RNA 
II) binds to the template DNA near replication origin. The 
plasmid replication is dependent on the primer formation 
(RNA II). Hybridization of RNA II to DNA is inhibited 
when a second RNA molecule RNA 1 (NAT RNA) binds 
to RNA II, which results in the alteration of secondary 
structure of RNA II [12]. 
(b) chromatin remodeling  
Chromatin remodeling is generally defined as any 
event that alters the nuclease sensitivity of a region of 
chromatin. These events can occur independently or in 
concert with other events, such as transcription [16]. S/AS 
pairs are especially abundant in imprinted loci, suggesting 
the putative role of non-coding RNA in gene silencing 
[6]. For example, in leukemia, an inverse relationship was 
observed between p15 antisense (p15AS) and p15 sense 
expression. The p15AS induces p15 silencing in cis and 
in trans through heterochromatin formation in leukemic 
cells and in mouse ES cells. 
(c) transcriptional interference
Transcriptional interference refers to the direct 
negative  impact  of  one  transcriptional  activity  on  a 
second  transcriptional  activity  in cis. This happens 
through 3 kinds of mechanisms: (1) occlusion in which 
the  passage  of  elongating  RNA  polymerases  (RNAPs) 
blocks the access to the promoter; (2) collisions between 
elongating  RNAPs,  moving  in  opposite  directions, 
leading  to  premature  termination  of  transcription;  and 
(3) ‘sitting duck’ interference which refers to the removal 
of promoter-bound complexes by the passage of RNAPs 
from the opposing promoter [17]. A non-translated AS 
RNA  (RnaG)  transcribes  in cis  on  the  complementary 
strand of icsA, a virulence gene of Shigella flexneri. The 
icsA and RnaG promoters are in opposite direction and 
120 bp apart. In vitro transcription from the strong RnaG 
promoter (aggressive) dramatically inhibits transcription 
from the weaker icsA promoter (sensitive) [18].
(d) rnA masking
RNA duplex formation may mask critical regulatory 
features within transcripts, thereby inhibiting the binding 
of  other  trans-acting  factors.  RNA  masking  intervenes 
mRNA  splicing,  transport,  polyadenylation,  translation 
and degradation [19]. Zeb2 NAT involved in epithelial–
mesenchymal  transition  (EMT)  uses  this  mechanism. 
Efficient translation of Zeb2 does not depend on 5’ cap 
structure,  but  on  internal  ribosome  entry  site  (IRES) 
embedded  in  an  intron  sequence  of  Zeb2  mRNA.  In 
epithelial cells, Zeb2 mRNA is fully spliced and cannot be 
translated. During EMT, Zeb2 NAT complements with the 
5’ splice site of the intron containing IRES in the 5’ UTR 
of Zeb2, which prevents the splicing of the intron required 
for efficient translation and expression of the Zeb2 protein 
[20].
(e) double stranded rnA-dependent mechanism
Duplex RNA can be recognized by RNAi machinery. 
These  dsRNAs  are  rapidly  processed  into  short  RNA 
duplexes of 21 to 28 nucleotides in length, which then 
guide  the  recognition  and  ultimately  the  cleavage  or 
translational repression of complementary single-stranded 
RNAs, such as messenger RNAs or viral genomic/anti-
genomic RNAs. In a recent experiment in X. Laevis, double 
stranded Slc34a/antisense Slc34a injected into the nucleus 
of xenopus oocytes were degraded into short RNAs of ~23 
bases within 4 h [21]. Similarly, more than 100 NATs have 
been processed into siRNA in D. melanogaster [10].
(f) translation interference
NATs can also prevent transcripts from translating 
by  simply  interfering  with  the  translation  apparatus. 
Antisense  PU.1  regulates  PU.1  expression  level  via 
translation interference. The absolute levels of PU.1, a 
transcription  factor  required  for  normal  hematopoiesis 
is critical for specifying cell fate, and, if perturbed, even 
modest  decreases  in  PU.1  can  lead  to  leukemias  and 
lymphomas. Antisense PU.1 forms complex with three 
translation  factors  eIF4A,  eEF1A  and  4E-BP1.    The 
complex  stalls  translation  between  the  initiation  and 
elongation steps [22]. 
nAts role in PAthology 
Although the physiological level of NATs is very low, Oncotarget 2010; 1:  447 - 452 449 www.impactjournals.com/oncotarget
their levels go up dramatically in disease. For example, 
β-secretase-1 (BACE1) is a crucial enzyme in Alzheimer’s 
disease pathophysiology and antisense BACE1 (BACE1-
AS)  is  markedly  up-regulated  in  brain  samples  from 
Alzheimer’s  disease  patients  [23].  Similarly,  antisense 
ApoE  is  100-fold  up-regulated  in  spinal  cord-injured 
C57BL/6 mice compared with normal levels [24]. 
Tumor  pathology  often  observes  AS  RNA  level 
changes and in turn shows aberrant regulation of cognate 
transcripts. In non-papillary clear-cell renal tumors, the 
NAT of hypoxia inducible factor α (HIFα) increases 10- 
to 100-fold [25]. Interestingly, a positive correlation of 
differential expression was observed for most sense and 
antisense transcript pairs between normal and malignant 
breast samples [26]. This suggests that aberrant expression 
of NATs may provide value as a diagnostic reagent. For 
neuroblastoma (NB), pediatric brain tumor condition, the 
ratio of antisense MYCN to MYCN is directly correlated 
with NB disease stage. In the more advanced NB stages 
and  NBs  with  MYCN-amplification,  relatively  more 
MYCN-AS is present as compared to MYCN. Further, 
expression of the antisense gene MYCN-AS is speculated 
to be relevant to the progression of NB [27].
Similar to tumor studies, the relevance of AS 
RNA levels to progression of cardiovascular disease is 
unknown.  In  a  recent  study,  the  analysis  in  peripheral 
blood mononuclear cells from 1098 patients of coronary 
artery  disease  demonstrated  positive  correlation  of AS 
noncoding RNA in the INK4 locus (ANRIL) expression 
with atherosclerosis [28].  Our recent study on non-coding 
RNA identified a natural AS transcript for tyrosine kinase 
containing immunoglobulin and epidermal growth factor 
homology domain-1 (tie-1), tie-1AS lncRNA in zebrafish, 
mouse  and  humans.  In  embryonic  zebrafish,  tie-1AS 
lncRNA transcript is expressed temporally and spatially 
in vivo with its native target, the tie-1 coding transcript 
and in additional locations (ear & brain). This argues for 
a  tie-1  gene  role  previously  unrecognized  in  the  brain 
and ear function, perhaps in the vasculature of these 
organs. In fact two recent studies implicate Angiopoietins, 
ligands for Tie’s, in lymphatic vessel development in ear 
[29,30]. Since the non-coding RNA for tie-1 is conserved 
in humans and mice, this paradigm of using non-coding 
RNA expression pattern to speculate putative novel gene 
function  (simply  based  on  expression  alone)  of  well-
studied genes is intriguing.
Mutations in Tie’s have been previously implicated in 
patients with vascular malformations [31-35]. Our studies 
showed that the ratio of tie-1 vs. tie-1AS lncRNA is altered 
in human vascular anomaly samples. The expression level 
of  tie-1AS is much lower than that of tie-1 in human 
placenta,  but  it  goes  up  dramatically  compared  to  the 
expression level of tie-1 in hemangioma samples [36]. 
We observed similar expression discrepancy between tie-
1 and tie-1AS in zebrafish cardiovascular mutant cloche 
[37] (Figure 1). Interestingly, this data correlates well with 
previous reported [18] in situ hybridization profile for tie-
1 in cloche embryos where the expression is quite low 
when compared to WT embryos. The vascular anomaly 
(disease) and the cloche (genetic mutant) results together 
suggest that when the cognate gene level (tie-1) is low, 
the cognate tie-1 AS levels are high suggesting an inverse 
relationship between the tie-1 and the AS transcript. In 
fact, this interpretation makes sense since we have shown 
the tie-1AS lncRNA selectively binds tie-1 mRNA in vivo 
and regulates tie-1 transcript levels [36]. Moreover, the 
normal expression levels of tie-1AS is a log lower than tie-
1 across different embryonic stages in zebrafish. 
In most of the examples to date levels of antisense 
RNA have been correlated to disease. However, studies 
reporting genetic mutations in the antisense RNA are not 
common. A genetic mutation that gives rise to pathologic 
antisense transcript is a 14;18 chromosome translocation 
observed  in  most  human  follicular  B-cell  lymphomas. 
This  translocation  not  only  creates  a  bcl-2/IgH  hybrid 
gene, but also gives rise to a bcl-2/IgH AS transcript. The 
AS transcript is merely present in the t(14;18)-positive, 
but not in the t(14;18)-negative lymphoid cell lines, and 
thus  appears  to  be  dependent  on  the  bcl-2/IgH  fusion 
[38].  Another recent example is observed in an individual 
with an inherited form of anemia (α-thalassemia). In this 
patient,  the  LUC7L  transcription  termination  sequence 
is deleted and LUC7L RNA extends into HBA2 locus 
and causes CpG island methylation of HBA2, a α-globin 
gene in erythroid cells. The methylation leads to silencing 
of HBA2 gene resulting in an inherited form of anemia 
α-thalassemia [39] in this subject.
nAts - ProMising future 
APPlicAtions
NATs hold immense potential for future applications. 
We will highlight three distinct areas of biology where 
NATs  are  expected  to  make  promising  contributions. 
More than 30 years ago, the inhibitory effects of antisense 
oligonucleotides  on  translation  were  observed  in vitro. 
Since then synthetic antisense oligonucleotides have been 
used  extensively  to  block  target  gene  expression  [40].   
However, not all sites in mRNA sequences respond to 
targeting. Only one out of ten randomly selected antisense 
Figure 1.  Real time PCR for tie-1 and tie-1AS across 
Clo+/+ and Clo+/- or Clo-/- embryos. Zebrafish cloche mutant 
embryos show aberrant level of tie-1AS compared with tie-1.Oncotarget 2010; 1:  447 - 452 450 www.impactjournals.com/oncotarget
oligonucleotides exhibit good activity [41]. A study by 
Van der Krol et al using the petunia as a model to test 
the effects of antisense gene fragments corresponding to 
different chromosomal location on flower pigmentation 
highlights this point. The patterns of pigmentation varied 
among flowers of different transgenic petunia with sub-
genomic fragments of antisense genes being ineffective 
in establishing a phenotype [42]. NATs are endogenous 
regulators  targeting  mRNA,  and  some  of  them  are 
processed into endogenous siRNAs [43]. Thereby, NATs 
are ideal models for designing antisense oligonucleotides.
The  second  example  highlights  the  role  of  NATs 
in a clinical trial setting. In clinical trials, an anticancer 
agent Gemcitabine can produce cytotoxic synergism with 
Cisplatin when given to cancer patients. It was proposed 
that  the  nucleotide  excision  repair  (NER)  process  was 
responsible for the synergism.  NER removes cisplatin-
DNA  adducts  by  a  series  of  steps  including  damage 
recognition, dual incision/excision, repair synthesis and 
ligation.  ERCC1  protein  is  an  important  factor  in  the 
incision process—the rate-limiting step of the pathway. 
Antisense  therapy  targeting  the  ERCC1  protein  was 
proposed as a target for this approach. As a result, NER 
activity was downregulated and the cytotoxic synergism 
between Gemcitabine and cisplatin was abolished [44].
The  third  example  highlights  the  role  of  NATs 
in  tumor  therapy. The  bcl-2/IgH  antisense  transcript  is 
presumed  to  be  responsible  for  the  overexpressed  bcl-
2,  the  root  of  oncogenicity  in  follicular  lymphomas. 
Therapeutic  ODNs  targeting  the  bcl-2/IgH  antisense 
transcript induced an early strong inhibition of cell growth 
and a late sudden cell death. The induction is restricted to 
follicular lymphomas which have t(14;18) chromosomal 
translocation,  but  not  effective  for  the  cells  carrying  a 
normal bcl-2 gene, suggesting tumor selectivity. However, 
antisense-oriented ODN, complementary to the bcl-2/IgH 
mRNA is ineffective [45].
suMMAry
NATs account for majority of non-coding RNAs in the 
vertebrate genome. Numerous mechanisms are utilized by 
NATs to regulate gene expression and these mechanisms 
span  over  both  plant  and  animal  kingdoms.  Recently, 
NATs have been identified in various diseases as well and 
the regulation that they mediate when lost may in part 
be responsible for disease progression and pathogenesis. 
Although most studies identify dysregulation of NATs, 
very  few  studies  have  identified  genetic  mutations  in 
them. As of now, NATs hold immense clinical value but 
their application is still at its infancy. 
AcKnoWledgeMents 
This  work  was  supported  by  American  Heart 
Association  postdoctoral  fellowship  to  KL,  NIH 
HL090712 to RR, Advancing Healthier Wisconsin and 
Children’s  Research  Institute  seed  funds  to  RR.  We 
apologize to authors whose work we have not been able to 
cite due to space limitations.
conflict of interest stAteMent
The authors do not have any conflict of interest to 
declare. 
references
1.  Lavorgna  G,  Dahary  D,  Lehner  B,  et  al.  In  search  of 
antisense. Trends Biochem Sci. 2004;  29: 88-94.
2.  Bovre  K  &  Szybalski  W.  Patterns  of  convergent  and 
overlapping transcription within the b2 region of coliphage 
lambda. Virology. 1969; 38: 614-26.
3.  Wek RC & Hatfield GW. Nucleotide sequence and in vivo 
expression of the ilvY and ilvC genes in Escherichia coli 
K12. Transcription from divergent overlapping promoters. 
J Biol Chem. 1986; 261: 2441-50.
4.  Wong  F,  Yuh  ZT,  Schaefer  EL,  et  al.  Overlapping 
transcription units in the transient receptor potential locus 
of Drosophila melanogaster. Somat Cell Mol Genet. 1987; 
13: 661-9.
5.  Rosok O & Sioud M. Systematic identification of sense-
antisense transcripts in mammalian cells. Nat Biotechnol. 
2004; 22: 104-8.
6.  Katayama  S,  Tomaru  Y,  Kasukawa  T,  et  al.  Antisense 
transcription in the mammalian transcriptome. Science. 
2005; 309: 1564-6.
7.  ENCODE  Project  Consortium,  Birney  E, 
Stamatoyannopoulos JA, et al. Identification and analysis 
of functional elements in 1% of the human genome by the 
ENCODE pilot project. Nature. 2007; 447: 799-816.
8.  Faghihi MA & Wahlestedt C. Regulatory roles of natural 
antisense  transcripts.  Nat  Rev  Mol  Cell  Biol.  2009;  10: 
637-43.
9.  Ge X, Wu Q, Jung YC, et al. A large quantity of novel 
human  antisense  transcripts  detected  by  LongSAGE. 
Bioinformatics. 2006; 22: 2475-9.
10.  Okamura  K,  Balla  S,  Martin  R,  et  al.  Two  distinct 
mechanisms  generate  endogenous  siRNAs  from 
bidirectional transcription in Drosophila melanogaster. Nat 
Struct Mol Biol. 2008; 15: 581-90.
11.  Faghihi MA, Zhang M, Huang J, et al. Evidence for natural 
antisense  transcript-mediated  inhibition  of  microRNA 
function. Genome Biol. 2010; 11: R56.
12.  Masukata H & Tomizawa J. Control of primer formation 
for ColE1 plasmid replication: conformational change of 
the primer transcript. Cell. 1986; 44: 125-36.
13.  International  Human  Genome  Sequencing  Consortium. 
Finishing the euchromatic sequence of the human genome. 
Nature. 2004; 431: 931-45.Oncotarget 2010; 1:  447 - 452 451 www.impactjournals.com/oncotarget
14.  Chen  J,  Sun  M,  Kent  WJ,  et  al.  Over  20%  of  human 
transcripts might form sense-antisense pairs. Nucleic Acids 
Res. 2004; 32: 4812-20.
15.  Lapidot  M  &  Pilpel  Y.  Genome-wide  natural  antisense 
transcription:  coupling  its  regulation  to  its  different 
regulatory mechanisms. EMBO Rep. 2006; 7: 1216-22.
16.  Aalfs  JD  &  Kingston  RE.  What  does  ‘chromatin 
remodeling’ mean? Trends Biochem Sci. 2000; 25: 548-55.
17.  Shearwin  KE,  Callen  BP  &  Egan  JB.  Transcriptional 
interference--a crash course. Trends Genet. 2005; 21: 339-
45.
18.  Liao  W,  Bisgrove  BW,  Sawyer  H,  et  al.  The  zebrafish 
gene cloche acts upstream of a flk-1 homologue to regulate 
endothelial cell differentiation. Development. 1997; 124: 
381-9.
19.  Prasanth KV & Spector DL. Eukaryotic regulatory RNAs: 
an answer to the ‘genome complexity’ conundrum. Genes 
Dev. 2007; 21: 11-42.
20.  Beltran  M,  Puig  I,  Peña  C,  et  al.  A  natural  antisense 
transcript  regulates  Zeb2/Sip1  gene  expression  during 
Snail1-induced  epithelial-mesenchymal  transition.  Genes 
Dev. 2008; 22: 756-69.
21.  Carlile M, Nalbant P, Preston-Fayers K, et al. Processing 
of  naturally  occurring  sense/antisense  transcripts  of  the 
vertebrate Slc34a gene into short RNAs. Physiol Genomics. 
2008; 34: 95-100.
22.  Ebralidze AK, Guibal FC, Steidl U, et al. PU.1 expression is 
modulated by the balance of functional sense and antisense 
RNAs regulated by a shared cis-regulatory element. Genes 
Dev. 2008; 22: 2085-92.
23.  Faghihi MA, Modarresi F, Khalil AM, et al. Expression of 
a noncoding RNA is elevated in Alzheimer’s disease and 
drives rapid feed-forward regulation of beta-secretase. Nat 
Med. 2008; 14: 723-30.
24.  Seitz  A,  Gourevitch  D,  Zhang  XM,  et  al.  Sense  and 
antisense transcripts of the apolipoprotein E gene in normal 
and ApoE knockout mice, their expression after spinal cord 
injury  and  corresponding  human  transcripts.  Hum  Mol 
Genet. 2005; 14: 2661-70.
25.  Reis EM, Nakaya HI, Louro R, et al. Antisense intronic 
non-coding RNA levels correlate to the degree of tumor 
differentiation  in  prostate  cancer.  Oncogene.  2004;  23: 
6684-92.
26.  Grigoriadis A, Oliver GR, Tanney A, et al. Identification of 
differentially expressed sense and antisense transcript pairs 
in breast epithelial tissues. BMC Genomics. 2009; 10: 324.
27.  Jacobs  JF,  van  Bokhoven  H,  van  Leeuwen  FN,  et  al. 
Regulation of MYCN expression in human neuroblastoma 
cells. BMC Cancer. 2009; 9: 239.
28.  Holdt LM, Beutner F, Scholz M, et al. ANRIL expression 
is associated with atherosclerosis risk at chromosome 9p21. 
Arterioscler Thromb Vasc Biol. 2010; 30: 620-7.
29.  Dellinger  M,  Hunter  R,  Bernas  M,  et  al.  Defective 
remodeling and maturation of the lymphatic vasculature in 
Angiopoietin-2 deficient mice. Dev Biol. 2008; 319: 309-
20.
30.  Kim  KE,  Cho  CH,  Kim  HZ,  et  al.  In  vivo  actions  of 
angiopoietins  on  quiescent  and  remodeling  blood  and 
lymphatic vessels in mouse airways and skin. Arterioscler 
Thromb Vasc Biol. 2007; 27: 564-70.
31.  Limaye  N,  Wouters  V,  Uebelhoer  M,  et  al.  Somatic 
mutations in angiopoietin receptor gene TEK cause solitary 
and multiple sporadic venous malformations. Nat Genet. 
2009; 41: 118-24.
32.  Vikkula M, Boon LM, Carraway KL 3rd, et al. Vascular 
dysmorphogenesis caused by an activating mutation in the 
receptor tyrosine kinase TIE2. Cell. 1996; 87: 1181-90.
33.  Wang H, Zhang Y, Toratani S, et al. Transformation of 
vascular endothelial cells by a point mutation in the Tie2 
gene from human intramuscular haemangioma. Oncogene. 
2004; 23: 8700-4.
34.  Bhandarkar  SS,  Jaconi  M,  Fried  LE,  et  al.  Fulvene-5 
potently inhibits NADPH oxidase 4 and blocks the growth 
of endothelial tumors in mice. J Clin Invest. 2009; 119: 
2359-65.
35.  Perry  B,  Banyard  J,  McLaughlin  ER,  et  al.  AKT1 
overexpression in endothelial cells leads to the development 
of cutaneous vascular malformations in vivo. Arch 
Dermatol. 2007; 143: 504-6.
36.  Li K, Blum Y, Verma A, et al. A noncoding antisense RNA 
in tie-1 locus regulates tie-1 function in vivo. Blood. 2010; 
115: 133-9.
37.  Li, K. Unpublished data.
38.  Capaccioli S, Quattrone A, Schiavone N, et al. A bcl-2/IgH 
antisense transcript deregulates bcl-2 gene expression in 
human follicular lymphoma t(14;18) cell lines. Oncogene. 
1996; 13: 105-15.
39.  Tufarelli C, Stanley JA, Garrick D, et al. Transcription of 
antisense RNA leading to gene silencing and methylation 
as  a  novel  cause  of  human  genetic  disease.  Nat  Genet. 
2003; 34: 157-65.
40.  Zamecnik PC. History of antisense oligonucleotides. In: 
Agrawal S, ed. Antisense therapy. Humana Press, Totowa, 
NJ. 1996; pp. 1-11.
41.  Bennett  CF  &  Cowsert  LM.  Antisense  oligonucleotides 
as a tool for gene functionalization and target validation. 
Biochim Biophys Acta. 1999; 1489: 19-30.
42.  van der Krol AR, Mur LA, de Lange P, et al. Inhibition of 
flower pigmentation by antisense CHS genes: promoter and 
minimal  sequence  requirements  for  the  antisense  effect. 
Plant Mol Biol. 1990; 14: 457-66.
43.  Werner A & Swan D. What are natural antisense transcripts 
good for? Biochem Soc Trans. 2010; 38: 1144-9.
44.  Yang  LY,  Li  L,  Jiang  H,  et  al.  Expression  of  ERCC1 
antisense RNA abrogates gemicitabine-mediated cytotoxic 
synergism  with  cisplatin  in  human  colon  tumor  cells 
defective in mismatch repair but proficient in nucleotide 
excision repair. Clin Cancer Res. 2000; 6: 773-81.Oncotarget 2010; 1:  447 - 452 452 www.impactjournals.com/oncotarget
45.  Morelli  S,  Delia  D,  Capaccioli  S,  et  al.  The  antisense 
bcl-2-IgH  transcript  is  an  optimal  target  for  synthetic 
oligonucleotides. Proc Natl Acad Sci U S A. 1997; 94: 
8150-5.